Matches in Nanopublications for { ?s ?p "[Findings from the human epidermal growth factor receptor 2 (HER2) -positive National Surgical Adjuvant Breast and Bowel Project (NSABP) B31 trial suggested that MYC/HER2 coamplification (> 5.0 copies/nucleus) was associated with additional benefit from adjuvant trastuzumab in patients with early-stage breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- assertion description "[Findings from the human epidermal growth factor receptor 2 (HER2) -positive National Surgical Adjuvant Breast and Bowel Project (NSABP) B31 trial suggested that MYC/HER2 coamplification (> 5.0 copies/nucleus) was associated with additional benefit from adjuvant trastuzumab in patients with early-stage breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP380545.RAW84CzsTwXkhDzaW0j1KV9XYJB7aYAI9XIdqMUhY1ez4130_assertion description "[Findings from the human epidermal growth factor receptor 2 (HER2) -positive National Surgical Adjuvant Breast and Bowel Project (NSABP) B31 trial suggested that MYC/HER2 coamplification (> 5.0 copies/nucleus) was associated with additional benefit from adjuvant trastuzumab in patients with early-stage breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP380545.RAW84CzsTwXkhDzaW0j1KV9XYJB7aYAI9XIdqMUhY1ez4130_provenance.
- assertion description "[Findings from the human epidermal growth factor receptor 2 (HER2) -positive National Surgical Adjuvant Breast and Bowel Project (NSABP) B31 trial suggested that MYC/HER2 coamplification (> 5.0 copies/nucleus) was associated with additional benefit from adjuvant trastuzumab in patients with early-stage breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP866167.RAVB-1W-5TGjN0gu_aA9NCSVdTBKd1LV3MJ_7-NS4qqlA130_assertion description "[Findings from the human epidermal growth factor receptor 2 (HER2) -positive National Surgical Adjuvant Breast and Bowel Project (NSABP) B31 trial suggested that MYC/HER2 coamplification (> 5.0 copies/nucleus) was associated with additional benefit from adjuvant trastuzumab in patients with early-stage breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP866167.RAVB-1W-5TGjN0gu_aA9NCSVdTBKd1LV3MJ_7-NS4qqlA130_provenance.
- NP582330.RACM-JH7p-KOzg3wd7GMGpz5RRJ8kdHNeuWfPPS-JrtCY130_assertion description "[Findings from the human epidermal growth factor receptor 2 (HER2) -positive National Surgical Adjuvant Breast and Bowel Project (NSABP) B31 trial suggested that MYC/HER2 coamplification (> 5.0 copies/nucleus) was associated with additional benefit from adjuvant trastuzumab in patients with early-stage breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP582330.RACM-JH7p-KOzg3wd7GMGpz5RRJ8kdHNeuWfPPS-JrtCY130_provenance.
- NP866169.RAIl0vG-UgMEhdufXTuUjL1Qj4GaJVt5TecZGDEVCF6i8130_assertion description "[Findings from the human epidermal growth factor receptor 2 (HER2) -positive National Surgical Adjuvant Breast and Bowel Project (NSABP) B31 trial suggested that MYC/HER2 coamplification (> 5.0 copies/nucleus) was associated with additional benefit from adjuvant trastuzumab in patients with early-stage breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP866169.RAIl0vG-UgMEhdufXTuUjL1Qj4GaJVt5TecZGDEVCF6i8130_provenance.